<DOC>
	<DOCNO>NCT01466166</DOCNO>
	<brief_summary>The primary purpose study observe patient treat KRYSTEXXA standard healthcare set order evaluate frequency severity infusion reaction , anaphylaxis immune complex related event . Additionally , serious adverse event associate KRYSTEXXA therapy identify .</brief_summary>
	<brief_title>Observational Study Use KRYSTEXXAÂ® Refractory Chronic Gout</brief_title>
	<detailed_description>This Phase 4 , multicenter , open-label , single-arm observational study KRYSTEXXA 8 mg i.v . every 2 week adult hyperuricemic patient gout refractory conventional therapy . Approximately 1500 patient enrol order observe treatment 500 patient approximately 300 center United States ( US ) . Study duration approximately 63 week , include 51 week treatment 12 week follow-up . The propose patient number 1 year duration study significantly extend patient exposure KRYSTEXXA compare pre-marketing control clinical trial . The design study follow FDA-approved Full Prescribing Information use KRYSTEXXA allow capture additional data relate safety efficacy KRYSTEXXA within standard healthcare setting .</detailed_description>
	<mesh_term>Gout</mesh_term>
	<criteria>Adults ( age 18 year ) chronic gout refractory conventional therapy , define patient fail normalize SUA whose sign symptoms inadequately control xanthine oxidase inhibitor maximum medically appropriate dose , drug contraindicate . Patients make decision , along treat physician , begin treatment KRYSTEXXA . Patients willing able give inform consent adhere visit/protocol schedule . Glucose6phosphate dehydrogenase ( G6PD ) deficiency Noncompensated congestive heart failure Pregnancy breast feed Prior treatment pegloticase another recombinant uricase Known allergy urate oxidase Prior treatment concomitant therapy polyethylene glycol ( PEG ) conjugate drug Recipient investigational drug within 4 week prior study drug administration plan take investigational agent study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>